North American generics specialist Nivagen Pharmaceuticals has secured an $8m credit facility with help from commercial finance advisors Business Capital, providing some of the firepower to launch almost 10 new generics this year.
The debt, which is secured on assets, will hand the firm “the necessary working capital to facilitate its growth as well as help fund certain development costs associated